PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study
- Conditions
- Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT02205476
- Locations
- 🇺🇸
Primeter outpatient surgery center, Atlanta, Georgia, United States
🇺🇸Body Aesthetic Research Center, Saint Louis, Missouri, United States
🇺🇸Kavali Plastic Surgery and Skin Renewal Center, Atlanta, Georgia, United States
Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 157
- Registration Number
- NCT02202837
- Locations
- 🇧🇪
ASZ Aalst, Aalst, Belgium
🇧🇪AZ Groeninge Campus Sint Maarten, Kortrijk, Belgium
🇧🇪CHU Ambroise Pare, Mons, Belgium
Defining Remission With Etanercept in AS in Real Life Clinical Practice
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT02202850
- Locations
- 🇧🇪
Grand Hopital de Charleroi, Gilly, Belgium
🇧🇪Algemeen Stedelijk Ziekenhuis, Aalst, Belgium
🇧🇪Biomedical Research Institute/ Department of Rheumatology, Genk, Belgium
Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.
- Conditions
- Complicated Skin and Soft Tissue Infection
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT02202135
- Locations
- 🇹🇷
Research site, Izmir, Turkey
A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions
- Conditions
- Healthy
- Interventions
- Drug: 3 mg PF-06412562 MR tablets_FastedDrug: 2 x 15 mg PF-06412562 MR tablets_FastedDrug: 2 x 15 mg PF-06412562 MR tablets_FedDrug: 10 mg PF-06412562 IR tablets
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02201511
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 59
- Registration Number
- NCT02201524
- Locations
- 🇺🇸
Northwest Arkansas Clinical Trials Center, PLLC/Hull Dermatology, PA, Rogers, Arkansas, United States
🇺🇸California Dermatology & Clinical Research Institute, Encinitas, California, United States
🇺🇸Clinical Science Institute, Santa Monica, California, United States
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 272
- Registration Number
- NCT02197130
- Locations
- 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of California, Irvine, Irvine, California, United States
🇬🇧University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
- Conditions
- Psoriasis Vulgaris
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT02193815
- Locations
- 🇩🇪
Bioskin GmbH, Hamburg, Germany
Absolute Bioavailability Of Bosutinib
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT02192294
- Locations
- 🇬🇧
Quotient Clinical, Ruddington Fields, Nottingham, United Kingdom
Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis
- Conditions
- Plaque Psoriasis
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 126
- Registration Number
- NCT02192164
- Locations
- 🇭🇺
Vas Megyei Markusovszky Korhaz/Borgyogyaszati Osztaly, Szombathely, Hungary
🇭🇺Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum/Bor- es Nemikortani Klinika, Debrecen, Hungary
🇭🇺Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Hungary